Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
July 09, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
July 02, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
May 21, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
May 13, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
April 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Metacrine to Present Phase 1 Results of MET409, an Optimized Next Generation FXR Agonist at The International Liver Congress (EASL) 2019
April 03, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Breathtec Announces Name Change to Algernon Pharmaceuticals
February 14, 2019 07:00 ET
|
Breathtec Biomedical Inc.
New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's...
Capital Digestive Care Taps Ramsey Daher, MD for Its Metro Offices
February 14, 2019 06:02 ET
|
Capital Digestive Care
Silver Spring, MD, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Capital Digestive Care welcomes Ramsey Daher, MD to its growing practice. Dr. Daher is now seeing patients at the company’s K Street, NW office...
Nash Pharmaceuticals to Present Data on Its Inflammatory Bowel Disease Research Program at The Digestive Disease Week Annual Conference
February 13, 2019 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...